Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line trial of BL-M07D1 versus pembrolizumab plus platinum chemotherapy in HER2-mutant advanced nonsquamous NSCLC
CTR20253668Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M07D1, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Oct 2025; status: active.
02
Drugs
BL-M07D1pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253668.